From the moment cancer is suspected, the clock starts ticking, yet delays in genetic testing, variation in protocols, and administrative friction can slow the path to optimal therapy. In this webinar, Avalon experts will share how combining liquid biopsy with standard tissue biopsy can improve the detection of actionable biomarkers, strengthen treatment matching, and reduce avoidable downstream costs and clinical risks.

We’ll also walk through how oncology analytics and automated prior authorization can help standardize testing pathways, accelerate authorizations, and shorten time-to-treatment, transforming oncology management into a faster, more precise, and more consistent experience for patients, providers, and payers.

Attendees will leave with a clear view of the clinical and financial opportunities, practical implementation levers, and how diagnostic intelligence can support better outcomes with less waste.